News & Media

Long-Term Safety and Tolerability of XCOPRI® (cenobamate tablets) CV Published in Epilepsia

SK life science Reports Effectiveness Of Long-Term Use With Cenobamate

SK life science To Present Latest Cenobamate Data at the American Academy of Neurology 2021 Virtual Annual Meeting

ONTOZRY® (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults

Cenobamate Receives Positive CHMP Opinion for Adjunctive Treatment of Focal-Onset (Partial-Onset) Seizures

SK Biopharmaceuticals To Sell Arvelle Therapeutics Stake As Part Of Angelini Pharma’s Acquisition Of Arvelle Therapeutics

SK life science Presents Latest Cenobamate Data at the American Epilepsy Society AES2020 Virtual Event

SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innovation

SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan

SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia

SK life science Expands Support for the Epilepsy Foundation to Advance Epilepsy Awareness, Research, Education and Care

Newly Published Study in Neurology Shows Cenobamate Significantly Reduced Seizure Frequency in Adults with Uncontrolled Partial-Onset (Focal) Seizures

SK life science Announces Results of Large, Open-Label Safety Study of Cenobamate Published in Epilepsia

SK life science Announces U.S. Availability of XCOPRI^® (cenobamate tablets) CV for the Treatment of Partial-Onset Seizures in Adults

SK Life Science, Inc.’s Coronavirus Update

European Medicines Agency Accepts Arvelle Therapeutics’ Marketing Authorization Application for Cenobamate for the Adjunctive Treatment of Focal-Onset Seizures in Adults

SK life science Receives Schedule V Designation from DEA for XCOPRI® (cenobamate tablets)

SK life science to Present Latest Cenobamate Data at the American Epilepsy Society 2019 Annual Meeting

SK Life Science, Inc. Announces FDA Acceptance of IND Application for Anti-Epileptic Drug Candidate SKL24741

FDA Approves XCOPRI® (cenobamate tablets) CV, an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.

Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology

New National Epilepsy Survey Reveals Significant Disconnects on Important Issues Among Patients, Caregivers and Healthcare Professionals

SK life science Expands Support for the J. Kiffin Penry Epilepsy Education Programs to Reach More Healthcare Providers

SK life science Provides Update on Recent Company Milestones and Accomplishments

SK life science to Showcase Scientific Data at the 2019 American Academy of Neurology Annual Meeting

SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe

SK life science announces FDA acceptance of NDA submission for cenobamate, an investigational antiepileptic drug

SK life science presents new data on its lead investigational compound, cenobamate, at the American Epilepsy Society 2018 Annual Meeting

SK life science honors Epilepsy Awareness Month with support for patients, advocates, caregivers, and healthcare providers

SK life science awards educational grant to J. Kiffin Penry Epilepsy Education Programs in support of neurology residents and epilepsy fellows

SK life science presents data on the investigational antiepileptic drug, cenobamate, at the American Academy of Neurology Annual Meeting 2018

SK life science to present data on cenobamate, an investigational antiepileptic compound, at ASCPT 2018 Annual Meeting

SK life science launches new corporate presence, expanded commercial operations in the United States.